KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Change in Acquisitions & Divestments (2016 - 2025)

Nektar Therapeutics (NKTR) has 16 years of Change in Acquisitions & Divestments data on record, last reported at $54.8 million in Q3 2025.

  • For Q3 2025, Change in Acquisitions & Divestments fell 15.9% year-over-year to $54.8 million; the TTM value through Sep 2025 reached $257.8 million, down 40.29%, while the annual FY2024 figure was $340.4 million, 47.71% down from the prior year.
  • Change in Acquisitions & Divestments reached $54.8 million in Q3 2025 per NKTR's latest filing, down from $68.6 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $1.2 billion in Q4 2021 and bottomed at -$626.4 million in Q4 2022.
  • Average Change in Acquisitions & Divestments over 5 years is $123.7 million, with a median of $148.0 million recorded in 2023.
  • The widest YoY moves for Change in Acquisitions & Divestments: up 640.54% in 2021, down 154.38% in 2021.
  • A 5-year view of Change in Acquisitions & Divestments shows it stood at $1.2 billion in 2021, then tumbled by 153.91% to -$626.4 million in 2022, then skyrocketed by 124.98% to $156.5 million in 2023, then plummeted by 58.39% to $65.1 million in 2024, then decreased by 15.84% to $54.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Acquisitions & Divestments were $54.8 million in Q3 2025, $68.6 million in Q2 2025, and $69.3 million in Q1 2025.